Novartis to cut more than 440 jobs in Britain

November 6, 2013

Swiss pharmaceuticals giant Novartis said Wednesday it aimed to slash more than 440 jobs in Britain, blaming industry-wide difficulties.

Novartis is considering closing its manufacturing site in Horsham, West Sussex, which would lead to the evaporation of 371 jobs, the told AFP in an email, confirming a report by the FierceBiotech website.

The closure was needed as Novartis attempts to adapt to "a challenging healthcare marketplace," it said, stressing that the decision was still subject to consultations with employees and final approval by its UK board.

"We understand that this will be a difficult time for potentially affected employees, their families and the wider Horsham community given the links the company has in the area," Novartis said, vowing to do its utmost to "make the process as straightforward and smooth as possible."

Two years ago, Novartis announced plans to halt manufacturing at the site and to cut staff numbers there from 950 to 450 people, but the group said Wednesday it now also aimed to close a unit dedicated to .

Novartis also said that cuts at its UK pharmaceuticals division in Frimley, Surrey, could impact another 72 .

The company currently employs more than 3,000 people in Britain.

Explore further: Roche 'extremely open' to talks with Novartis: report

Related Stories

Roche 'extremely open' to talks with Novartis: report

October 1, 2013
The head of Swiss pharmaceutical giant Roche is open to renewed cooperation with competitor Novartis, he told the Financial Times in an interview published Tuesday.

Novartis announces 2,000 job losses, profits up

October 25, 2011
Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Novartis insists its flu vaccines are safe

October 25, 2012
Swiss pharmaceutical giant Novartis insisted early Thursday that its flu vaccines were safe despite a sales ban by Italy, Switzerland and Austria.

EU drug regulator OKs Novartis' meningitis B shot

November 16, 2012
Europe's top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.

Japan to raid Novartis over alleged data fabrication: reports

September 27, 2013
Japanese authorities are preparing to raid the local arm of Swiss pharmaceutical giant Novartis over data fabrication claims, reports said Friday.

Novartis chief sees sales dip until mid-2013

October 7, 2012
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.